Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluoxetine for Refractory SMAS with SSD
NCT07115472Completed
- Sponsor
- Xijing Hospital of Digestive Diseases
- Start
- Jan 2024
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of fluoxetine in superior mesenteric artery syndrome and somatic symptom disorder (SSD), sponsored by Xijing Hospital of Digestive Diseases. Primary endpoint: Proportion of patients achieving Gastric Outlet Obstruction Scoring System (GOOSS) score >= 2 at 6 months. Started Jan 2024; status: completed.
02
Drugs
fluoxetine
03
Conditions
superior mesenteric artery syndromesomatic symptom disorder (SSD)
Beyond the preview
Go deeper on NCT07115472.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07115472.